Cited 49 times in
Recurrence after Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjögren's Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김응권 | - |
dc.contributor.author | 서경률 | - |
dc.contributor.author | 정소향 | - |
dc.contributor.author | 홍사민 | - |
dc.date.accessioned | 2014-12-21T16:51:57Z | - |
dc.date.available | 2014-12-21T16:51:57Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96498 | - |
dc.description.abstract | BACKGROUND: The aim of this study was to evaluate the prevalence of long-term recurrence after topical nonpreserved methylprednisolone pulse therapy for the treatment of keratoconjunctivitis sicca (KCS) with Sjögren's syndrome. METHODS: A total of 106 eyes of 53 Sjögren's syndrome patients were included in the study. All patients were treated with topical nonpreserved 1% methylprednisolone solution. Initial therapy consisted of eyedrops 4 times a day for 2 weeks, and then patients were reevaluated and tapered off the medication every 2 weeks until discontinuation. Tear film breakup time (TBUT), Schirmer test, corneal fluorescein staining, and subjective symptom scores were measured. Additionally, impression cytology of the bulbar conjunctiva was performed. The over-all success rates and success period were determined using the Kaplan-Meier survival curve. RESULTS: A reduction in subjective symptoms and fluorescein staining, and an improvement in TBUT and Schirmer test results, was observed after treatment (P<0.001). Impression cytology specimens revealed a significantly increased number of periodic acid-Schiff-positive cells after treatment. After the first pulse therapy, mean survival was 56.6 weeks and 11 (20.8%) patients recurred. After the second pulse therapy, mean survival was 72.4 weeks and only 1 patient recurred. No serious complications, including intraocular pressure elevation and cataract formation, were encountered during the entire follow-up period. CONCLUSIONS: Topical nonpreserved methylprednisolone pulse therapy proved to be a safe, effective long-term treatment of improving subjective and objective dry eye factors in KCS patients with Sjögren's syndrome. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 78~82 | - |
dc.relation.isPartOf | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Topical | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glucocorticoids/administration & dosage* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Keratoconjunctivitis Sicca/drug therapy* | - |
dc.subject.MESH | Keratoconjunctivitis Sicca/etiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methylprednisolone/administration & dosage* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ophthalmic Solutions/administration & dosage | - |
dc.subject.MESH | Preservatives, Pharmaceutical | - |
dc.subject.MESH | Pulse Therapy, Drug | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Sjogren's Syndrome/complications | - |
dc.subject.MESH | Sjogren's Syndrome/drug therapy* | - |
dc.subject.MESH | Tears/metabolism | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Recurrence after Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjögren's Syndrome | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Samin Hong | - |
dc.contributor.googleauthor | Terry Kim | - |
dc.contributor.googleauthor | Kyoung Yul Seo | - |
dc.contributor.googleauthor | Eung Kweon Kim | - |
dc.contributor.googleauthor | So-Hyang Chung | - |
dc.identifier.doi | 10.1089/jop.2006.0091 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00831 | - |
dc.contributor.localId | A01870 | - |
dc.contributor.localId | A03633 | - |
dc.contributor.localId | A04395 | - |
dc.relation.journalcode | J01654 | - |
dc.identifier.eissn | 1557-7732 | - |
dc.identifier.pmid | 17341155 | - |
dc.identifier.url | http://online.liebertpub.com/doi/abs/10.1089/jop.2006.0091 | - |
dc.contributor.alternativeName | Kim, Eung Kweon | - |
dc.contributor.alternativeName | Seo, Kyuong Yul | - |
dc.contributor.alternativeName | Chung, So Hyang | - |
dc.contributor.alternativeName | Hong, Sa Min | - |
dc.contributor.affiliatedAuthor | Kim, Eung Kweon | - |
dc.contributor.affiliatedAuthor | Seo, Kyuong Yul | - |
dc.contributor.affiliatedAuthor | Chung, So Hyang | - |
dc.contributor.affiliatedAuthor | Hong, Sa Min | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 78 | - |
dc.citation.endPage | 82 | - |
dc.identifier.bibliographicCitation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.23(1) : 78-82, 2007 | - |
dc.identifier.rimsid | 36118 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.